1. Home
  2. SAFE vs MPLT Comparison

SAFE vs MPLT Comparison

Compare SAFE & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$14.62

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$30.74

Market Cap

1.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAFE
MPLT
Founded
2016
2018
Country
United States
United States
Employees
N/A
133
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
SAFE
MPLT
Price
$14.62
$30.74
Analyst Decision
Hold
Strong Buy
Analyst Count
10
7
Target Price
$19.00
$32.67
AVG Volume (30 Days)
355.3K
272.1K
Earning Date
04-30-2026
05-28-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.40
N/A
Revenue
$385,552,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.31
N/A
P/E Ratio
$37.93
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$12.24
52 Week High
$17.16
$33.28

Technical Indicators

Market Signals
Indicator
SAFE
MPLT
Relative Strength Index (RSI) 43.17 59.25
Support Level $14.45 $26.70
Resistance Level $16.31 $32.68
Average True Range (ATR) 0.44 2.39
MACD -0.09 -0.31
Stochastic Oscillator 22.76 80.49

Price Performance

Historical Comparison
SAFE
MPLT

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

Share on Social Networks: